does medicaid cover glp-1 drugs Rhode Island considers ending coverage of for weight loss β’ Rhode Island Current π’ New Resource Alert! We've
Description
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two gut hormones, defined incretins, responsible for the amplification of insulin secretion after oral glucose intake
Shima Hadidchi

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials
However, individuals with obesity or insulin resistance may experience enhanced clinical and cognitive outcomes
